GLP-1 RECEPTOR AGONIST. 2010
Add to clipboard
2: GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. 2010
Add to clipboard
3: Hepatic-portal vein infusions of GLP-1 reduce meal size and increase c-Fos expression in the NTS, AP, and CeA in rats. 2010
Add to clipboard
4: GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. 2010
Add to clipboard
5: Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. 2010
Add to clipboard
6: GLP-1 playing the role of a gut regulatory compound. 2010
Add to clipboard
7: Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. 2010
Add to clipboard
8: Chronic Administration of the Glucagon-Like Peptide-1 (GLP-1) Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats. 2010
Add to clipboard
9: GLP-1 Receptor Stimulation Depresses Heart Rate Variability and Inhibits Neurotransmission to Cardiac Vagal Neurons. 2010
Add to clipboard
10: A Novel Human Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1. 2010
Add to clipboard
11: Central GLP-1 Actions on Energy Metabolism. 2010
Add to clipboard
12: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. 2009
Add to clipboard
13: GLP-1 regulates gastroduodenal motility involving cholinergic pathways. 2009
Add to clipboard
14: The effects of GLP-1 infusion in the hepatic portal region on food intake. 2009
Add to clipboard
15: Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. 2009
Add to clipboard
16: Hindbrain cocaine- and amphetamine-regulated transcript induces hypothermia mediated by GLP-1 receptors. 2009
Add to clipboard
17: Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. 2009
Add to clipboard
18: Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats. 2009
Add to clipboard
19: Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. 2009
Add to clipboard
20: A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. 2009
Add to clipboard
21: The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. 2009
Add to clipboard
22: Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. 2009
Add to clipboard
23: Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. 2009
Add to clipboard
24: Role and development of GLP-1 receptor agonists in the management of diabetes. 2009
Add to clipboard
25: GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. 2008
Add to clipboard
26: Differential inhibition of galanin- and ghrelin-induced food intake by i.c.v. GLP-1(7-36)-amide. 2008
Add to clipboard
27: GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. 2008
Add to clipboard
28: Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. 2008
Add to clipboard
29: Modulation of taste sensitivity by GLP-1 signaling. 2008
Add to clipboard
30: GLP-1: physiological effects and potential therapeutic applications. 2008
Add to clipboard
31: CNS GLP-1 regulation of peripheral glucose homeostasis. 2008
Add to clipboard
32: The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. 2008
Add to clipboard
33: Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. 2008
Add to clipboard
34: Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. 2008
Add to clipboard
35: Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements. 2008
Add to clipboard
36: Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit? 2008
Add to clipboard
37: Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. 2008
Add to clipboard
38: Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. 2008
Add to clipboard
39: Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. 2007
Add to clipboard
40: Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. 2007
Add to clipboard
41: Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. 2007
Add to clipboard
42: Biology of incretins: GLP-1 and GIP. 2007
Add to clipboard
43: The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. 2007
Add to clipboard
44: GLP-1 analogs: satiety without malaise? 2007
Add to clipboard
45: [Glucagon-like peptide 1 (GLP-1)] 2007
Add to clipboard
46: [GLP-1. Generalities and incretin-nutrient interaction] 2007
Add to clipboard
47: Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. 2007
Add to clipboard
48: Blockade of central GLP-1 receptors prevents CART-induced hypophagia and brain c-Fos expression. 2006
Add to clipboard
49: Involvement of CRF on the anorexic effect of GLP-1 in layer chicks. 2006
Add to clipboard
50: GLP-1 based therapy for type 2 diabetes. 2006
Add to clipboard
51: Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. 2006
Add to clipboard
52: Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. 2006
Add to clipboard
53: Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. 2006
Add to clipboard
54: Gastrointestinal satiety signals in humans--physiologic roles for GLP-1 and PYY? 2006
Add to clipboard
55: Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. 2006
Add to clipboard
56: Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. 2006
Add to clipboard
57: Effects of a preload on reduction of food intake by GLP-1 in healthy subjects. 2006
Add to clipboard
58: Distribution of proglucagon mRNA and GLP-1 in the brainstem of chicks. 2005
Add to clipboard
59: Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue. 2005
Add to clipboard
60: Glucagon-like peptide 1(GLP-1) in biology and pathology. 2005
Add to clipboard
61: Nutrient-stimulated GLP-1 release in normal-weight men and women. 2005
Add to clipboard
62: The physiological role of GLP-1 in human: incretin, ileal brake or more? 2005
Add to clipboard
63: GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. 2005
Add to clipboard
64: Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. 2005
Add to clipboard
65: Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. 2005
Add to clipboard
66: Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. 2005
Add to clipboard
67: Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. 2005
Add to clipboard
68: Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. 2004
Add to clipboard
69: Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. 2004
Add to clipboard
70: Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. 2004
Add to clipboard
71: [Glucagon-like peptide-1(GLP-1)] 2004
Add to clipboard
72: Glucagon-like peptide 1 (GLP-1) and eating. 2004
Add to clipboard
73: A new Alzheimer's disease interventive strategy: GLP-1. 2004
Add to clipboard
74: A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. 2004
Add to clipboard
75: [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2] 2004
Add to clipboard
76: Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. 2004
Add to clipboard
77: On the physiology of GIP and GLP-1. 2004
Add to clipboard
78: Physiology of GLP-1--lessons from glucoincretin receptor knockout mice. 2004
Add to clipboard
79: Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. 2004
Add to clipboard
80: Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. 2003
Add to clipboard
81: Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. 2003
Add to clipboard
82: Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats. 2003
Add to clipboard
83: Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. 2003
Add to clipboard
84: GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. 2003
Add to clipboard
85: Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. 2003
Add to clipboard
